← All Posts
VER
Vertex Pharmaceuticals Incorporated
May 14, 2026
•
Author: Phil Ratcliff
| Item |
Proposal |
Vote |
| 1.01 |
Sangeeta Bhatia |
✓ For(130.78)
|
| 1.02 |
Lloyd Carney |
✓ For(130.78)
|
| 1.03 |
Alan Garber |
✓ For(130.78)
|
| 1.04 |
Reshma Kewalramani |
✗ Against(130.78)
|
| 1.05 |
Michel Lagarde |
✓ For(130.78)
|
| 1.06 |
Jeffrey Leiden |
✗ Against(130.78)
|
| 1.07 |
Diana McKenzie |
✓ For(130.78)
|
| 1.08 |
Bruce Sachs |
✓ For(130.78)
|
| 1.09 |
Jennifer Schneider |
✓ For(130.78)
|
| 1.10 |
Nancy Thornberry |
✓ For(130.78)
|
| 1.11 |
Nominee Withdrawn |
✓ For(130.78)
|
| 2 |
Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2026. |
✓ For(130.78)
|
| 3 |
Advisory vote to approve named executive officer compensation. |
✓ For(130.78)
|
| 4 |
Approval of 2026 Stock and Option Plan. |
✓ For(130.78)
|
| 5 |
Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. |
✗ Against(130.78)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial